Ardent Announces Planned CEO Transition
Christine Parrish will become Chief Executive Officer effective August 1, 2026, succeeding Erica Nemser, who will continue to support the company through the transition and then serve as Executive Chair.
Low Light, High Fidelity: Hinalea's VNIR Ultra Helps Researchers See What Others Miss
It captures 301 spectral bands across the 400 to 1,000 nm range using a high-sensitivity sCMOS sensor, so researchers get high-fidelity spectral and spatial detail without the excessively long exposures low-light samples usually demand.
Pasqal and Aeponyx Launch PIC Packaging Center of Competency at C2MI
The initiative also brings together HOP Technologies and Phantom Photonics, backed by $4 million in federal and provincial funding out of a $7.9 million total project budget. The first phase will build low-volume manufacturing capacity, with a second phase targeting production of over 500,000 modules per year.
pH7 Secures Up to $5M to Advance On-Site Copper Cathode Technology
The technology converts low-grade sulfide ore directly into 99.9% pure copper cathodes on-site while producing green hydrogen as a by-product. If successful, the project could support future scale-up across Canada's mining sector.
なぜ私たちはDioseve社に投資したのか
Dioseve社は、iPS細胞由来の卵巣サポート技術を活用し、既存のIVFプロセスの中で卵子成熟の生物学的メカニズムそのものを構築しています。これにより、患者の治療向上を図りながら、実際の臨床現場のワークフローにも適合し、これまでニーズはあるものの明確な解決策がなかった問題に応えようとしています。
Why We Invested in Dioseve
Reproductive biology has emerged as an important frontier in hard tech, with the potential to reshape infertility. Dioseve is building at that intersection, which is why we chose Dioseve as Pangaea’s first startup investment in Japan. We have been laying the groundwork to support more hard tech founders in the country, and Dioseve is the first example of that strategy in action.
Nautilus’ Facility Cooling Distribution Unit Exceeds Performance Benchmarks for Next-Generation AI GPU Workloads
Nautilus validated its next‑generation EcoCore cooling unit for Vera Rubin‑class AI GPU clusters, proving it can safely and efficiently handle 4 MW‑plus high‑density workloads that legacy systems struggle to support.
Why We’re Doubling Down on Kanvas
At Pangaea Ventures, we invest in bold hard tech innovations reshaping the future of industry and solving our planet’s (and its people’s) most pressing challenges. Kanvas Biosciences is a quintessential example leveraging groundbreaking spatial biology technology and precision microbiome therapeutics to address untapped opportunities in medicine and beyond. Here’s why we’ve invested again.
Kanvas Biosciences Secures $48M Series A to Advance Microbiome Therapeutics for Cancer Patients
Co-led by DCVC and Lions Capital with participation from the Gates Foundation, ATHOS, Germin8, Ki Tua Fund, Pangaea Ventures and others, the round will fund clinical trials for Kanvas’ lead drug candidates and more.
CarbonCure Appoints Yuliya Kravtsov as Chief Executive Officer
With decades of experience scaling industrial businesses, Kravtsov will focus on expanding CarbonCure’s CO₂ utilization technology across more producers and regions.
pH7 Technologies Announces Oversubscribed Series B Final Closing
The funding will accelerate commercialization and global deployment of pH7’s closed-loop platform, enabling economic recovery of critical minerals from low-grade ores, tailings, and complex feedstocks that were previously uneconomic to process.
Aspect Biosystems Announces $280 Million Partnership with the Government of Canada
Aspect Biosystems has announced a $280M partnership with Government of Canada to accelerate development of its bioengineered cellular medicines for serious metabolic and endocrine diseases.
pH7 Expands Vancouver Facility to Strengthen North American Supply of Critical Platinum Group Metals
pH7 Technologies is expanding its Vancouver facility to boost North American recovery of critical platinum group metals from recycled materials, while cutting wastewater, energy use, and carbon footprint relative to conventional refining.
Kanvas receives greenlight for First Patient In (FPI) for Phase 1 clinical trial of KAN-004
Kanvas Biosciences has received the green light to begin enrolling and treating patients in a Phase 1 clinical trial of KAN-004, a live biotherapeutic designed to treat immune checkpoint inhibitor–induced colitis
Versogen and InSolare Energy partner to advance AEM electrolyser technology in India
InSolare Energy and Versogen have entered a technology transfer and strategic collaboration to jointly develop and commercialize advanced AEM electrolyzer stacks for India’s green hydrogen market.
Kanvas Bio Adds Dr. Stephen Quake to Board of Directors
Kanvas Biosciences has welcomed Dr. Stephen Quake to its Board of Directors, adding one of the world’s leading bioengineers to an already strong team.
Tidal Vision Named to 2026 Cleantech100
The honor validates Tidal Vision’s thesis that biosolutions win at scale only when they outcompete on performance, economics, and ease of use, and highlights the team’s progress bringing chitosan‑based chemistry into water treatment, agriculture, and materials applications.
NewLeaf Introduces EPA-Registered TS601 Biofungicide
TS601 builds on NewLeaf’s PPFM platform and induced systemic resistance mode of action, giving growers a new biological tool to protect yield while supporting more sustainable production.
pH7 Named a Finalist in Future of Mining Challenge
We’re proud to see pH7 Technologies named a finalist in Wheaton Precious Metals’ 2025/2026 Future of Mining Challenge, recognizing solutions that can reshape how the industry sources critical metals.
ChEmpower Announces Chakra™, the First Functional Pad for Abrasive-Free Planarization
By replacing abrasive slurries with a chemically reactive pad and polishing fluid, Chakra is designed to improve yield, reduce water and waste, and help enable advanced AI chips, HBM, and cutting‑edge packaging flows.